NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5146.54M
Enterprise Value 379.2M
Trailing P/E N/A
Forward P/E 1-1.68
PEG Ratio (5 yr expected) 1-0.01
Price/Sales (ttm)14.74
Price/Book (mrq)3.08
Enterprise Value/Revenue 37.96
Enterprise Value/EBITDA 6-0.90

Trading Information

Stock Price History

Beta (5Y Monthly) 2.52
52-Week Change 3-26.83%
S&P500 52-Week Change 321.38%
52 Week High 33.2700
52 Week Low 31.1600
50-Day Moving Average 31.3791
200-Day Moving Average 31.8403

Share Statistics

Avg Vol (3 month) 31.32M
Avg Vol (10 day) 3943.67k
Shares Outstanding 594.55M
Float 77.56M
% Held by Insiders 11.24%
% Held by Institutions 143.06%
Shares Short (Jan 30, 2020) 44.65M
Short Ratio (Jan 30, 2020) 42.97
Short % of Float (Jan 30, 2020) 46.43%
Short % of Shares Outstanding (Jan 30, 2020) 44.92%
Shares Short (prior month Dec 30, 2019) 42.64M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 210:1
Last Split Date 3Jun 25, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-886.68%

Management Effectiveness

Return on Assets (ttm)-54.41%
Return on Equity (ttm)-133.51%

Income Statement

Revenue (ttm)9.95M
Revenue Per Share (ttm)0.14
Quarterly Revenue Growth (yoy)1,401.10%
Gross Profit (ttm)-40.58M
EBITDA -87.9M
Net Income Avi to Common (ttm)-90.54M
Diluted EPS (ttm)-1.2770
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)78.28M
Total Cash Per Share (mrq)1
Total Debt (mrq)36.03M
Total Debt/Equity (mrq)91.89
Current Ratio (mrq)5.80
Book Value Per Share (mrq)0.50

Cash Flow Statement

Operating Cash Flow (ttm)-78.64M
Levered Free Cash Flow (ttm)-44.75M